newsfilter
← Latest News
PR Newswire·

Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference

STOCKHOLM, Nov. 9, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the